The Chemotherapy-Induced Neutropenia (CIN) Treatment Market is expected to reach USD 651.26 million in 2025 and grow at a CAGR of 3.58% to reach USD 776.49 million by 2030. Amgen, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring Pharmaceuticals I
Schwenkglenks, MatthiasTaylor & FrancisLeukemia & LymphomaPettengell R, Schwenkglenks M. Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups. Leuk Lymphoma 2011;52:1133-1136....
This report lists the top Chemotherapy-Induced Neutropenia (CIN) Treatment companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Chemotherapy-Induced Neutropenia (CIN) Treatment ...
BMC Cancer (2021) 21:549 https://doi.org/10.1186/s12885-021-08323-4 RESEARCH Open Access Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small- cell lung cancer: a pooled analysis of 6 randomized trials Piera Gargiulo1†, Laura Arenare1†, Cesare Gridelli2, ...
Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour OBJECTIVES to evaluate quality of life in patients with malignant brain tumour with stable disease after combined treatments in comparison to patients with... Anna,R,Giovagnoli - ...
Treatment I. Consider discontinuing or delaying chemotherapy in animals with neutrophil counts of <1000/μL, and starting prophylactic broad-spectrum antibiotics, because they are predisposed to sepsis (Kociba, 2000). II. Lithium carbonate (11 mg/kg PO BID for 6 weeks) may reverse marrow hypopla...
after cardiovascular illness.3,4 Chemotherapy is among the standard treatments for cancer patients.5,6 One of the major side effects of anticancer regimen is myelosuppression.7 Potentially life-threatening febrile neutropenia (FN), intravenous antibiotic treatment and prolonged hospitalization might be a ...
Emprical antiinfective treatmentAntiinfective prophylaxisGranulocyte-colony stimulating factorSummaryFebrile Neutropenia is a relevant factor for mortality after chemotherapy. Dependent upon factors like duration of neutropenia (鈮 7 d means high-risk situation), patient- and disease specific criteria e.g. ...
Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer Background: Surgery is the primary treatment for patients with stage I, II, or IIIA non鈥搒mall-cell lung cancer (NSCLC). However, long-term survival of NS... GV Scagliotti -...
†Do not administer Neulasta®between 14 days before and 24 hours after administration of cytotoxic chemotherapy. Keeping patients’ treatment plans on track See the Data For innovation and reliable supply, choose Onpro® View Details Onpro®has broad national coverage and financial support opti...